Value-based pricing models for innovative pharmaceuticals

Abstract

Innovative pharmaceuticals have revolutionized healthcare, offering new treatments and cures for previously untreatable conditions. However, their high costs pose significant challenges to healthcare systems worldwide. Traditional pricing models often fail to reflect the true value of these innovations, leading to inefficiencies and limited patient access. Value-based pricing (VBP) models, which align drug prices with their clinical and economic value, present a potential solution. This article explores the principles, benefits, challenges, and future prospects of VBP for innovative pharmaceuticals.